Annovis Bio (ANVS) said Tuesday it was granted a US patent for methods to treat and prevent acute brain or nerve injuries using buntanetap.
The newly issued patent is based on buntanetap's ability to reduce neurotoxicity and address neurodegenerative processes, making it applicable to conditions like stroke, ischemia, traumatic brain injury, and micro infarcts, the company said.
With the US patent, Annovis Bio said it now holds global protection for buntanetap to treat acute neurodegenerative disorders, following similar patents granted in the European Union, Japan, and worldwide.
Price: 4.79, Change: +0.02, Percent Change: +0.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.